Phase I Dose Escalation Study of VS-5584 in Subjects With Advanced Non-Hematologic Malignancies or Lymphoma

NCT01991938 · clinicaltrials.gov ↗
PHASE1
Phase
TERMINATED
Status
75
Enrollment
INDUSTRY
Sponsor class

Stopped Lack of recruitment and the company's decision to de-prioritize 5584 development

Conditions

Interventions

Sponsor

Verastem, Inc.